- Home
- MTNB vs ADXN Comparison
MTNB vs ADXN Comparison
Compare MTNB & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- ADXN
- Stock Information
- Founded
- MTNB 2013
- ADXN 2002
- Country
- MTNB United States
- ADXN Switzerland
- Employees
- MTNB N/A
- ADXN N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- MTNB Health Care
- ADXN Health Care
- Exchange
- MTNB Nasdaq
- ADXN Nasdaq
- Market Cap
- MTNB 7.9M
- ADXN 8.0M
- IPO Year
- MTNB N/A
- ADXN N/A
- Fundamental
- Price
- MTNB $1.68
- ADXN $8.09
- Analyst Decision
- MTNB Hold
- ADXN Strong Buy
- Analyst Count
- MTNB 1
- ADXN 1
- Target Price
- MTNB N/A
- ADXN $30.00
- AVG Volume (30 Days)
- MTNB 1.4M
- ADXN 683.0
- Earning Date
- MTNB 08-14-2025
- ADXN 09-01-2025
- Dividend Yield
- MTNB N/A
- ADXN N/A
- EPS Growth
- MTNB N/A
- ADXN N/A
- EPS
- MTNB N/A
- ADXN 0.10
- Revenue
- MTNB N/A
- ADXN $278,508.00
- Revenue This Year
- MTNB N/A
- ADXN $86.57
- Revenue Next Year
- MTNB N/A
- ADXN N/A
- P/E Ratio
- MTNB N/A
- ADXN $0.73
- Revenue Growth
- MTNB N/A
- ADXN N/A
- 52 Week Low
- MTNB $0.47
- ADXN $6.51
- 52 Week High
- MTNB $4.25
- ADXN $11.84
- Technical
- Relative Strength Index (RSI)
- MTNB 52.06
- ADXN 47.89
- Support Level
- MTNB $1.64
- ADXN $7.51
- Resistance Level
- MTNB $1.90
- ADXN $8.21
- Average True Range (ATR)
- MTNB 0.24
- ADXN 0.11
- MACD
- MTNB -0.05
- ADXN 0.00
- Stochastic Oscillator
- MTNB 38.38
- ADXN 47.54
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.